Breaking News Instant updates and real-time market news.

AMC

AMC Entertainment

$6.47

-0.155 (-2.34%)

, SKT

Tanger Factory

$16.36

-0.01 (-0.06%)

08:45
01/10/20
01/10
08:45
01/10/20
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: AMC Entertainment (AMC) 29.14% +2.74, Tanger Factory (SKT) 65.36% +1.92, Childrens Place (PLCE) 2.37% +1.24, FuelCell (FCEL) 38.63% +0.47, Novavax (NVAX) 65.92% +0.18, ProShares Ultra DJ UBS Crude Oil (UCO) 2.54% +0.18, Tailored Brands (TLRD) 6.79% +0.18, Cronos Group (CRON) 9.51% +0.17, Verastem (VSTM) 44.69% +0.17, and Virgin Galactic (SPCE) 3.37% +0.16.

AMC

AMC Entertainment

$6.47

-0.155 (-2.34%)

SKT

Tanger Factory

$16.36

-0.01 (-0.06%)

PLCE

Children's Place

$65.14

0.48 (0.74%)

FCEL

FuelCell

$2.19

-0.095 (-4.16%)

NVAX

Novavax

$4.01

-0.265 (-6.20%)

UCO

Universal Compression

$19.45

-0.51 (-2.56%)

TLRD

Tailored Brands

$4.10

-0.18 (-4.21%)

CRON

Cronos Group

$7.06

0.42 (6.33%)

VSTM

Verastem

$1.80

0.065 (3.76%)

SPCE

Virgin Galactic

$12.05

0.645 (5.66%)

  • 22

    Jan

AMC AMC Entertainment
$6.47

-0.155 (-2.34%)

11/22/19
RILY
11/22/19
NO CHANGE
RILY
B. Riley FBR downgrades Cinemark and Marcus, cuts exhibitor targets
B. Riley FBR analyst Eric Wold revisited his exhibitor coverage heading into the "most important stretch" of the Q4 film slate, which will bring Frozen II, Jumanji: The Next Level, and Star Wars: The Rise of Skywalker to screens. However, with the quarter-to-date box office down 14.7%, the analyst now believes Q4 could be relatively flattish year-over-year versus consensus expectations for a mid-single-digit increase. As a result, he lowered his Q4 estimates for the group and believes the full-year 2019 box office could decline around 4.0%. Wold downgraded both Cinemark (CNK) and Marcus (MCS) to Neutral from Buy, saying short-term domestic box office movements are more likely to influence valuation decisions over the next 12-18 months. The analyst also lowered his price target for Buy-rated AMC Entertainment (AMC) to $15 from $19, for Buy-rated Imax (IMAX) to $30 from $34, and for Neutral-rated National CineMedia (NCMI) to $7.50 from $8.50.
12/18/19
BOFA
12/18/19
DOWNGRADE
BOFA
Underperform
AMC Entertainment downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Bryan Goldberg downgraded AMC Entertainment to Underperform from Neutral.
12/18/19
BOFA
12/18/19
DOWNGRADE
Target $7
BOFA
Underperform
BofA/Merrill downgrades AMC Entertainment to Underperform with $7 target
BofA/Merrill analyst Bryan Goldberg downgraded AMC Entertainment (AMC) to Underperform from Neutral with a price target of $7, down from $14. The analyst sees a "tough" compares for the 2020 film slate and highlights the lapping of Stubs A-List price increase. Further, he sees a continued rise in perceived competition from small screen competitors such as Netflix (NFLX) as well as high leverage at AMC.
12/18/19
12/18/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. FedEx (FDX) downgraded to Perform from Outperform at Oppenheimer with analyst Scott Schneeberger saying the company's Q2 results were weaker than expected on a lighter than expected Express/Ground segment performance. 2. Domino's Pizza (DPZ) downgraded to Neutral from Buy at Longbow with analyst Alton Stump citing valuation. 3. AMC Entertainment (AMC) downgraded to Underperform from Neutral at BofA/Merrill with analyst Bryan Goldberg saying he sees a "tough" compares for the 2020 film slate and highlights the lapping of Stubs A-List price increase. 4. Halliburton (HAL) downgraded to Market Perform from Outperform at BMO Capital with analyst Daniel Boyd saying while down 7% year-to-date, Halliburton is the best performing large cap energy stock over the past three months on positive changes in frac fundamentals, macro improvements, and high short interest. 5. Galapagos (GLPG) downgraded to Neutral from Buy at Citi with analyst Nick Nieland saying he views the current valuation as fair and sees fewer clinical catalysts into the first half of 2020. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SKT Tanger Factory
$16.36

-0.01 (-0.06%)

03/25/19
BOSC
03/25/19
INITIATION
Target $27
BOSC
Outperform
Tanger Factory initiated with an Outperform at Boenning & Scattergood
Boenning & Scattergood analyst Merrill Ross initiated Tanger Factory with an Outperform and $27 price target.
05/09/19
GSCO
05/09/19
DOWNGRADE
Target $15
GSCO
Sell
Tanger Factory downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Caitlin Burrows downgraded Tanger Factory to Sell from Neutral and lowered her price target for the shares to $15 from $19.80. The analyst does not expect a near-term reacceleration in the company's earnings growth.
PLCE Children's Place
$65.14

0.48 (0.74%)

12/12/19
DADA
12/12/19
NO CHANGE
Target $80
DADA
Buy
Children's Place price target lowered to $80 from $135 at DA Davidson
DA Davidson analyst John Morris lowered his price target on Children's Place to $80 after its Q3 results and a cut in its FY19 guidance amid "heavy promotional pressure", which the management believes to be contained to Q4. The analyst still keeps his Buy rating and believes that the headwinds will turn into tailwinds in 2020 amid anniversarying of industry consolidation and as the fulfillment/personalization investments begin to wane. Morris further anticipates revenue contribution starting in the Spring from the re-launch of Gymboree.
12/12/19
12/12/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Home Depot (HD) downgraded to Accumulate from Buy at Gordon Haskett with analyst Chuck Grom saying he left Home Depot's analyst meeting yesterday with "mixed emotions." 2. 3M (MMM) downgraded to Sell from Neutral at UBS analyst Markus Mittermaier citing his caution heading into 2020 related to volume, pricing, and the potential polyfluoroalkyl substance contamination liability. 3. Children's Place (PLCE) downgraded to Neutral from Outperform at Wedbush and to Underperform from Neutral at BofA/Merrill. 4. Bright Scholar (BEDU) downgraded to Neutral from Buy at Goldman Sachs with analyst Christine Cho saying she sees higher cost pressure from recent acquisitions after the company reported "another earnings miss" in fiscal Q4. 5. West Pharmaceutical (WST) downgraded to Underperform from Neutral at BofA/Merrill with analyst Juan Avendano citing a difficult prior year comps weighing on the company's 2020 prospects, along with its "near all-time high valuation" limiting its multiple expansion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/12/19
WEDB
12/12/19
DOWNGRADE
Target $60
WEDB
Neutral
Children's Place downgraded to Neutral at Wedbush, price target slashed to $60
Wedbush analyst Jen Redding downgraded Children's Place to Neutral from Outperform with a price target of $60, down from $130. In a research note to investors, Redding says that while she sees Children's Place as a "strong" value story, she has less visibility into the company's margin turnaround given that the mix between e-commerce and brick & mortar stores has turned out to be a more material drag on gross margin than we originally anticipated. Although stable merchandise margins demonstrated in Q3 ndicate that the promotional atmosphere is heightened but controlled, Redding says she now sees the structural factors driving e-commerce to a higher percentage of sales as enough to depress gross margin and keep shares grounded in the near-term.
12/12/19
DBAB
12/12/19
NO CHANGE
Target $75
DBAB
Buy
Children's Place price target lowered to $75 from $103 at Deutsche Bank
Deutsche Bank analyst Tiffany Kanaga lowered her price target for Children's Place to $75 from $103 but maintains a Buy rating on the shares after the company reported a "very disappointing print."
FCEL FuelCell
$2.19

-0.095 (-4.16%)

06/06/19
COWN
06/06/19
DOWNGRADE
Target $1
COWN
Market Perform
FuelCell downgraded to Market Perform from Outperform at Cowen
Cowen analyst Jeffrey Osborne downgraded FuelCell to Market Perform from Outperform and lowered his price target on the shares to $1.00 from $2.75 following the company's announcement of the hiring of a restructuring firm and dismissal of its CEO.
12/11/19
CHLM
12/11/19
INITIATION
Target $0.5
CHLM
Hold
FuelCell reinstated with a Hold at Craig-Hallum
Craig-Hallum analyst Eric Stine reinstated coverage of FuelCell with a Hold rating and $.50 price target.
06/06/19
OPCO
06/06/19
DOWNGRADE
OPCO
Perform
Oppenheimer downgrades FuelCell to Perform on restructuring, CEO exit
Oppenheimer analyst Colin Rusch downgraded FuelCell Energy to Perform from Outperform without a price target. With the company entering into a full restructuring via Huron Consulting and CEO Chip Bottone being terminated, its strategy for moving forward "has become increasingly more difficult to predict," Rusch tells investors in a research note. The analyst had anticipated FuelCell would restructure its debt, but he says it is now unclear how it will move forward both from a capital structure and also from a management perspective. As a result, Rusch is stepping to the sidelines" until a strategy and leadership team is in place."
06/06/19
06/06/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Qorvo (QRVO) downgraded to Equal Weight from Overweight at Barclays with analyst Blayne Curtis citing the company's higher relative valuation, concerns of increased radio frequency competition, and potential further impacts from the trade war for the downgrade. 2. Spirit Airlines (SAVE) downgraded to Neutral from Buy at Goldman Sachs with analyst Catherine O'Brien saying there is downside risk to the consensus earnings forecasts for Spirit while United's estimates have appropriately incorporated tougher second half 2019 comparables. 3. Orange SA (ORAN) downgraded to Equal Weight from Overweight at Morgan Stanley. 4. Cloudera (CLDR) downgraded two notches to Hold from Strong Buy at Needham, to Neutral from Buy at Citi, to Hold from Buy at Stifel, and to Market Perform from Outperform at Raymond James. 5. FuelCell (FCEL) downgraded to Perform from Outperform at Oppenheimer and to Market Perform from Outperform at Cowen. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NVAX Novavax
$4.01

-0.265 (-6.20%)

11/27/19
RILY
11/27/19
INITIATION
Target $12
RILY
Buy
Novavax resumed with a Buy at B. Riley FBR
B. Riley FBR resumed coverage of Novavax with a Buy rating and $12 price target.
08/14/19
HCWC
08/14/19
NO CHANGE
Target $17
HCWC
Buy
Novavax price target raised to $17 from $10 at H.C. Wainwright
H.C. Wainwright analyst Vernon Bernardino raised his price target for Novavax to $17 from $10 and reiterates a Buy rating on the shares. The stock closed yesterday up 28c to $4.30. The agreement on a Phase 3 trial design for NanoFlu that Novavax announced with the FDA on August 5 sets the stage for the program to accelerate, Bernardino tells investors in a research note. The analyst believes Novavax's NanoFlu vaccine can now be approved in 2022 versus his prior expectation of 2024. He looks for share price appreciation to allow "successful financings" in 2020 and 2021, positioning Novavax to independently launch commercial NanoFlu worldwide.
09/24/19
SBSH
09/24/19
NO CHANGE
Target $15
SBSH
Buy
Citi drops Novavax target to $15 on 'unusually high cash challenges'
Citi analyst Joel Beatty continues to view the combined value of Novavax's respiratory syncytial virus and flu vaccines are higher than the company's current enterprise value of ~$400M. However, he lowered his price target for the shares to $15 from $19 to reflect the "unusually high cash challenges for the company." Beatty expects positive NanoFlu results in Q1 of 2020, but says any upside to the stock from these results is unlikely to be sustained unless Novavax is also able to obtain meaningful non-dilutive funding related to one or both of its lead vaccine candidates. The analyst keeps a Buy rating on the shares, adding that the company's two late-stage vaccines may attract interest from large pharma.
09/10/19
OPCO
09/10/19
NO CHANGE
Target $13
OPCO
Outperform
Novavax price target lowered to $13 from $25 at Oppenheimer
Oppenheimer analyst Kevin DeGeeter lowered his price target for Novavax to $13 from $25 after the company filed an 8-K disclosing EMA declined to support use of the conditional marketing authorization pathway for approval of ResVax in the EU. While the decision does not formally prevent Novavax from filing with EMA, the analyst believes that approval without an additional clinical trial is now unlikely. DeGeeter reiterates an Outperform rating based on continued optimism for a positive Phase III result for NanoFlu in Q1 2020. Furthermore, given increased clarity on the regulatory path for ResVax, he believes there is stronger logic for management to seek a sale of the company following NanoFlu data
UCO Universal Compression
$19.45

-0.51 (-2.56%)

TLRD Tailored Brands
$4.10

-0.18 (-4.21%)

06/13/19
RILY
06/13/19
NO CHANGE
Target $7
RILY
Neutral
Tailored Brands price target lowered to $7 from $10 at B. Riley FBR
B. Riley FBR analyst Susan Anderson lowered her price target for Tailored Brands to $7 from $10 saying "challenges remain" after the company's Q2 guidance missed expectations. The analyst believes Tailored Brands is "on the right track" with its changes to the product assortment, cost savings program, and omni-channel initiatives, but she remains on the sidelines pending stabilization in same-store-sales and greater visibility into its long-term performance. Anderson keeps a Neutral rating on the shares.
03/14/19
RILY
03/14/19
DOWNGRADE
Target $11
RILY
Neutral
Tailored Brands downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Susan Anderson downgraded Tailored Brands to Neutral from Buy and cut her price target for the shares to $11 from $20. The analyst sees a lack of near-term visibility into when same-store-sales will stabilize.
03/14/19
JEFF
03/14/19
NO CHANGE
Target $19
JEFF
Buy
Jefferies cuts Tailored Brands target to $19, admits to making 'terrible' call
In a research note titled "How Could We Be So Wrong?" Jefferies analyst Randal Konik lowered his price target for Tailored Brands to $19 from $24. "Let's begin with our call has been terrible here," Konik writes. Tailored's business is "challenged and is getting worse," visibility seems very low and management seems to be questioning the execution of some of its strategies, Konik says following the company's Q4 results. He believes the stock will remain in the "penalty box" until the business can show some stabilization. However, with a "cheap" valuation and "less significant downside potential" from current levels, Konik keeps a Buy rating on Tailored Brands.
CRON Cronos Group
$7.06

0.42 (6.33%)

11/05/19
BOFA
11/05/19
NO CHANGE
BOFA
BofA says Mexico cannabis legalization 'still in play' in 2020 after extension
BofA Merrill Lynch analyst Christopher Carey noted that Mexico's Supreme Court has granted an extension until April 30, 2020 for Congress to legalize all forms of cannabis, writing in its decision that considering the complexity of the issue it grants the extension "exceptionally and for one time only." He views this as an important development for the industry since, in addition to opening a potentially large market, it will put even more pressure on U.S. federal action as the country will potentially "place the US between 2 of only 3 countries in the world to have legalized cannabis for recreational use." 9% of Mexico's population of 131M is estimated to have consumed cannabis in 2018 and the legal market could be worth $1B by 2024, according to BDS Analytics, noted Carey. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), Tilray (TLRY) and Trulieve Cannabis (TCNNF).
10/22/19
PIPR
10/22/19
NO CHANGE
Target $12
PIPR
Overweight
Piper cuts targets in Cannabis, says Canopy and Cronos best positioned
Piper Jaffray analyst Michael Lavery revisited the four Canadian licensed producers under his coverage, namely Aurora Cannabis (ACB), Canopy Growth (CGC), Cronos Group (CRON) and Tilray (TLRY). The analyst continues to believe Canopy and Cronos look best positioned. Both companies have strong cash positions to facilitate growth and have good visibility on key strategic priorities, Lavery tells investors in a research note. The analyst cut his estimates for Tilray, but he keeps an Overweight rating on the shares as he still sees growth potential in both Europe and the U.S. Lavery believes Aurora lacks visibility on key strategic growth priorities and he keeps a Neutral rating on the shares. The analyst lowered his price target for Aurora to $4 from $7, for Canopy to $36 from $40, for Cronos to $12 from $18, and for Tilray to $31 from $72.
10/18/19
STFL
10/18/19
UPGRADE
STFL
Buy
Cronos Group upgraded to Buy from Hold at Stifel
Stifel analyst Andrew Carter upgraded Cronos Group (CRON) to Buy from Hold with a price target of C$14.00, down from C$16.50. The analyst Cronos is "unconstrained" in its ability to invest towards a $200B global opportunity with C$2B in cash on hand the resources of Altria Group (MO), Carter tells investors in a research note titled "Crowning a New King in the North." The analyst believes Cronos will show an "enhanced revenue growth profile" that leverages the distribution capabilities of Altria to build its U.S. CBD business and demonstrate "break-through product potential" in the Canadian vapor segment. Given the company's "advantaged and enhanced position," investors should buy Cronos shares following their recent pullback, says Carter.
10/16/19
BOFA
10/16/19
NO CHANGE
BOFA
BofA lowers cannabis stock price targets on further sales estimate changes
Following yesterday's rally in cannabis stock's driven by Aphria's (APHA) earnings, BofA Merrill Lynch analyst Christopher Carey said he doesn't see a case for sustainable upside yet until consensus estimates are cut further, which he thinks will ensue with the calendar Q3 results from the group. The reason that industry sales could be flat to down quarter-over-quarter sector-wide is that the cannabis industry is going from a period of inventory build to one of inventory "de-load," said Carey. Given his sales estimate revisions, he has lowered his price target on Aurora Cannabis (ACB) shares to $5 from $6, cut his Canopy Growth (CGC) price target to $23 from $27, trimmed his Cronos Group (CRON) target to $13 from $16 and decreased his Hexo (HEXO) target to $2 from $2.50. Carey keeps a Buy rating on Cronos, has Neutral ratings on Aurora and Canopy and maintains an Underperform rating on Hexo.
VSTM Verastem
$1.80

0.065 (3.76%)

06/20/19
JONE
06/20/19
DOWNGRADE
JONE
Hold
Verastem downgraded to Hold from Buy at JonesTrading
06/20/19
BTIG
06/20/19
DOWNGRADE
BTIG
Neutral
Verastem downgraded to Neutral from Buy at BTIG
BTIG analyst Robert Hazlett downgraded Verastem to Neutral from Buy.
06/20/19
JONE
06/20/19
NO CHANGE
JONE
Hold
JonesTrading downgrades Verastem as CEO marks third major management exit
As previously reported, JonesTrading analyst Matthew Cross downgraded Verastem to Hold from Buy after news that CEO Robert Forrester will be leaving the company. While this setback would have been "unexpected but manageable" by itself, the fact that this is the third major management departure gives him reason to pause and re-evaluate his view on the company, Cross tells investors. Despite Copiktra's initial difficulty, his talks with management leave him with reasons to be optimistic about a turnaround if the company can hit some of its goals in the next six months, added Cross.
05/14/19
ROTH
05/14/19
NO CHANGE
Target $4
ROTH
Buy
Verastem price target lowered to $4 from $14 at Roth Capital
Roth Capital analyst Jotin Marango lowered his price target for Verastem to $4 from $14 as the company's Q1 update leaves him uncertain about the strategy and extra time that Verastem may need to eventually unlock that commercial value. The analyst reiterates a Buy rating on the shares.
SPCE Virgin Galactic
$12.05

0.645 (5.66%)

12/09/19
12/09/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zillow (ZG) initiated with a Neutral at Citi. 2. Virgin Galactic (SPCE) initiated with an Overweight at Morgan Stanley. 3. Plains All American (PAA) and Plains GP Holdings (PAGP) initiated with a Neutral at Goldman Sachs. 4. Strata Skin Sciences (SSKN) initiated with a Buy at Ladenburg. 5. Zymeworks (ZYME) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/09/19
MSCO
12/09/19
INITIATION
Target $22
MSCO
Overweight
Virgin Galactic initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Virgin Galactic with an Overweight rating and $22 price target.
12/09/19
MSCO
12/09/19
INITIATION
Target $22
MSCO
Overweight
Morgan Stanley cites 'biotech-type risk/reward' in Virgin Galactic initiation
Morgan Stanley analyst Adam Jonas initiated coverage of Virgin Galactic with an Overweight rating and $22 price target, telling investors that he sees a "biotech-type risk/reward" for the shares. He believes the addressable market for space tourism is niche, but supported by a range of industries. However, Jonas believes what is really likely to drive upside for the stock is what he calls "the third phase of the VG business model," namely hypersonic point-to-point, or P2P, air travel. His $22 price target factors in $10 per share in value for space tourism and $12 per share for the hypersonic opportunity, Jonas noted.
11/21/19
11/21/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Noble Energy (NBL) initiated with a Buy at MKM Partners. 2. Smith & Nephew (SNN) initiated with a Buy at Citi. 3. Dell Technologies (DELL) initiated with a Neutral at Nomura Instinet. 4. Virgin Galactic (SPCE) initiated with an Outperform at Credit Suisse. 5. Alector (ALEC) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/17/20
01/17
16:30
01/17/20
16:30
Options
Preliminary option volume of 28.7M today »

Preliminary option volume…

NSCO

Nesco Holdings

$5.12

0.025 (0.49%)

16:26
01/17/20
01/17
16:26
01/17/20
16:26
Syndicate
Nesco Holdings requests withdrawal of registration statement »

Nesco Holdings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$18.54

-0.075 (-0.40%)

, CMCSA

Comcast

$47.48

0.62 (1.32%)

16:20
01/17/20
01/17
16:20
01/17/20
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

The major averages were…

GPS

Gap

$18.54

-0.075 (-0.40%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

CMCSK

Comcast

$0.00

(0.00%)

PLAY

Dave & Buster's

$47.35

5.3 (12.60%)

KKR

KKR

$31.20

0.7 (2.30%)

BA

Boeing

$324.11

-7.89 (-2.38%)

JNJ

Johnson & Johnson

$149.07

0.82 (0.55%)

SWK

Stanley Black & Decker

$172.63

2.18 (1.28%)

TWOU

2U

$22.84

1.05 (4.82%)

BE

Bloom Energy

$9.70

0.43 (4.64%)

MGPI

MGP Ingredients

$38.16

-14.74 (-27.86%)

FAST

Fastenal

$36.77

-0.55 (-1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 20

    Jan

  • 22

    Jan

  • 23

    Jan

  • 29

    Jan

  • 29

    Jan

  • 31

    Jan

  • 26

    Feb

  • 27

    Feb

  • 09

    Mar

  • 17

    Mar

APLS

Apellis

$40.43

0.03 (0.07%)

16:18
01/17/20
01/17
16:18
01/17/20
16:18
Hot Stocks
Apellis CEO sells 30.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
01/17/20
01/17
16:17
01/17/20
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
01/17/20
01/17
16:16
01/17/20
16:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
01/17/20
01/17
16:15
01/17/20
16:15
General news
Treasury Market Summary »

Treasury Market Summary:…

LGC

Legacy Acquisition Corp

$10.33

(0.00%)

16:08
01/17/20
01/17
16:08
01/17/20
16:08
Hot Stocks
Legacy Acquisition Corp extends date to consummate proposed business combination »

Legacy Acquisition Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNUS

Genius Brands

$0.33

-0.015 (-4.41%)

16:04
01/17/20
01/17
16:04
01/17/20
16:04
Syndicate
Breaking Syndicate news story on Genius Brands »

Genius Brands files $50M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$90.21

1.28 (1.44%)

16:04
01/17/20
01/17
16:04
01/17/20
16:04
Periodicals
Best Buy board opens investigation into CEO's personal conduct, WSJ says »

The board of Best Buy is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.